SG11202109531UA - Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions - Google Patents

Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions

Info

Publication number
SG11202109531UA
SG11202109531UA SG11202109531UA SG11202109531UA SG11202109531UA SG 11202109531U A SG11202109531U A SG 11202109531UA SG 11202109531U A SG11202109531U A SG 11202109531UA SG 11202109531U A SG11202109531U A SG 11202109531UA SG 11202109531U A SG11202109531U A SG 11202109531UA
Authority
SG
Singapore
Prior art keywords
insertions
compounds
cancer cells
activity against
tumor activity
Prior art date
Application number
SG11202109531UA
Other languages
English (en)
Inventor
Jacqulyne Robichaux
John Heymach
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of SG11202109531UA publication Critical patent/SG11202109531UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202109531UA 2019-03-29 2020-03-27 Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions SG11202109531UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962826758P 2019-03-29 2019-03-29
PCT/US2020/025478 WO2020205632A1 (en) 2019-03-29 2020-03-27 Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions

Publications (1)

Publication Number Publication Date
SG11202109531UA true SG11202109531UA (en) 2021-09-29

Family

ID=72666271

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109531UA SG11202109531UA (en) 2019-03-29 2020-03-27 Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions

Country Status (12)

Country Link
US (1) US20220175778A1 (zh)
EP (1) EP3946632A4 (zh)
JP (1) JP2022527499A (zh)
KR (1) KR20210145161A (zh)
CN (1) CN113766955A (zh)
AU (1) AU2020256119A1 (zh)
BR (1) BR112021019376A2 (zh)
CA (1) CA3132834A1 (zh)
IL (1) IL286576A (zh)
MX (1) MX2021011925A (zh)
SG (1) SG11202109531UA (zh)
WO (1) WO2020205632A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3956035A4 (en) * 2019-04-17 2023-01-25 Board of Regents, The University of Texas System CANCER COMPOUNDS CARRYING EGFR MUTATIONS RESISTANT TO TYROSINE KINASE INHIBITORS
UY39593A (es) * 2020-12-29 2022-07-29 Spectrum Pharmaceuticals Inc Tratamiento para tumores sólidos malignos
WO2024036234A1 (en) * 2022-08-09 2024-02-15 Heligenics Inc. Method for evaluating clinical relevance of genetic variance

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101317809B1 (ko) * 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR102355121B1 (ko) * 2011-12-14 2022-02-09 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 암 요법을 위한 병립 유전자 비활성화 생물표식과 표적들
JP2019519772A (ja) * 2016-05-31 2019-07-11 ネステク ソシエテ アノニム Ｈｅｒ２及びｈｅｒ３の経路サブタイピングに基づく乳癌患者の薬物療法の選択方法
AU2017363199B2 (en) * 2016-11-17 2023-08-17 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations
US20220041751A1 (en) * 2018-12-21 2022-02-10 Board Of Regents, The University Of Texas System Combination therapy for the treatment of cancer

Also Published As

Publication number Publication date
WO2020205632A8 (en) 2021-10-14
CA3132834A1 (en) 2020-10-08
EP3946632A1 (en) 2022-02-09
US20220175778A1 (en) 2022-06-09
WO2020205632A1 (en) 2020-10-08
MX2021011925A (es) 2021-11-03
IL286576A (en) 2021-12-01
BR112021019376A2 (pt) 2021-12-07
KR20210145161A (ko) 2021-12-01
AU2020256119A1 (en) 2021-10-07
EP3946632A4 (en) 2023-01-04
CN113766955A (zh) 2021-12-07
JP2022527499A (ja) 2022-06-02

Similar Documents

Publication Publication Date Title
IL286742A (en) Compounds with antitumor activity against cancer cells carrying insertions in exon 20 of her2 or egfr
EP3541832A4 (en) COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS CARRIER OF EGFR OR HER2 MUTATIONS EXON 20
IL286576A (en) Compounds with antitumor activity against cancer cells containing exon 21 her2 insertions
IL277373A (en) Compounds with antitumor activity against cancer cells with a mutation in exon 19 of HER2
IL267786A (en) An optimal strategy for exon-skipping modifications using CRISPR/CAS9 with triple-stranded sequences
MX2021005561A (es) Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco.
EP4038639A4 (en) INTEGRATED NEUTRON SHIELDING IN A CONTAINER
SG10201811701YA (en) Non-human animals having a humanized a proliferation-inducing ligand gene
EP2755674A4 (en) ANTAGONISTS OF PRODUCTS OF THE HS-459642-UNIGEN CLUSTER TO AVOID PROLIFERATION, DEVELOPMENT, OR DIFFERENTIATION OF STEM CELLS WITH CANCER STEM CELLS
EP3303363A4 (en) INTRA-PATIENT GENOMIC HETEROGENEITY OF UNIQUE CIRCULATING TUMOR CELLS (CTC) ASSOCIATED WITH THE HETEROGENEITY OF PHENOTYPIC CTC IN ANDROGEN-INDEPENDENT METASTASIC PROSTATE CANCER (MCRPC)
SG11202009088VA (en) Compound with anticancer activity
WO2015015301A3 (en) Cancer therapy with silver nanoparticles
PL439505A1 (pl) Osłona z kurtyną wodną
EP3884958A4 (en) VACCINATION WITH MICROVESICLES DERIVED FROM TUMOR CELLS FOR THE TREATMENT OF CANCER
MX2018006776A (es) Usos de pirimido-piridazinonas para tratar el cancer.
EP3353553A4 (en) USE OF ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR THE THERAPEUTIC SELECTION OF PATIENTS WITH METASTATIC CANCER PROSTATE RESISTANT TO CASTRATION (CPRCM)
GB202211202D0 (en) Headphones with EMF shielding material
GB201918313D0 (en) Cells for treating cancer
GB202002073D0 (en) Horizontal cells
EP3909963A4 (en) COMPLEX IRIDIUM COMPOUND
EP3570683A4 (en) ACTIVE YEAST DIETARY SUPPLEMENT BOLUS
ZA202007636B (en) Feed additive and feed containing the feed additive
PL4025581T3 (pl) Nowe kompleksy platyny iv o zasadniczo zwiększonej skuteczności przeciwnowotworowej
WO2015057737A3 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF VprBP-RELATED CANCERS
GB202115108D0 (en) 3D cancer cells